^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CHGA (Chromogranin A)

    i
    Other names: CHGA, Chromogranin A, Parathyroid Secretory Protein 1, Pituitary Secretory Protein I, Chromogranin-A, SP-I, Betagranin (N-Terminal Fragment Of Chromogranin A), Pancreastatin, Chromofungin, Vasostatin, Parastatin, Catestatin, CGA, CgA
    Associations

    News

    Trials
    6d
    Expression of ubiquitin carboxyl-terminal hydrolase isozyme L1 and chromogranin A regulated via histone-modification through Rho/ERK/NFκB signaling in oxaliplatin-resistant colorectal cancer cells. (PubMed, Int J Med Sci)
    Both CHGA and UCHL1-activated transcription were regulated through the Rho/ERK/NF-κB signaling pathways by histone modifications of H3K4 trimethylation. In this study, Rho/ERK/NFκB signaling-mediated CHGA and UCHL1 expression, which is regulated through histone modifications and affects OXA-resistant CRC EMT outcomes, was assessed, and its potential as an early detection biomarker and prognostic indicator was explored with clinical applications.
    Journal
    |
    CHGA (Chromogranin A)
    |
    oxaliplatin
    9d
    Atypical, Clinically Silent, Locally Advanced Pheochromocytoma Revealing Von Hippel-Lindau Type 2C Phenotype: A Case Report. (PubMed, Cureus)
    Genetic testing identified a pathogenic VHL mutation: NM_000551.4(VHL):c.508G>A, consistent with VHL type 2C phenotype. Systematic screening for other VHL-associated lesions was negative. This case highlights the diagnostic challenge posed by clinically silent pheochromocytomas and underscores the importance of genetic evaluation in atypical adrenal tumors.
    Journal
    |
    VHL (von Hippel-Lindau tumor suppressor) • CHGA (Chromogranin A)
    |
    VHL mutation
    18d
    Altered vasomotor function and endothelial impairment in a neuroendocrine tumor mouse model. (PubMed, Am J Surg)
    Elevated serotonin levels may further compromise vasopressin-mediated vasoconstriction. The presence of NET metastases alters vascular responsiveness, which may contribute to hemodynamic instability.
    Preclinical • Journal
    |
    ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • CHGA (Chromogranin A)
    29d
    Determining Prognosis in Patients With Carcinoid Syndrome: A Retrospective Single-Center Cohort Study. (PubMed, J Natl Compr Canc Netw)
    Patients with CS are likely to succumb to their disease, with >90% of mortality being NET-specific. Age, tumor grade, primary lung origin, and CgA levels were independent predictors of mortality. These findings indicate that there is an urgent need for advances in therapeutic options for patients with CS.
    Retrospective data • Journal
    |
    CHGA (Chromogranin A)
    1m
    A novel gene signature based on Like-Smith family members-related genes for predicting the prognosis of hepatocellular carcinoma. (PubMed, Transl Cancer Res)
    The novel two-gene signature comprising PITX2 and CHGA effectively predicts survival outcomes in HCC patients and is closely associated with tumor metabolism and immune regulation. This signature may serve as a valuable tool for prognostic evaluation and guiding personalized treatment strategies for HCC patients.
    Journal • Gene Signature
    |
    CHGA (Chromogranin A)
    1m
    Mature tertiary lymphoid structures tumor microenvironment-based risk model to assess patients with pancreatic ductal adenocarcinoma. (PubMed, Transl Cancer Res)
    We successfully developed a novel TLS-derived gene signature that robustly predicts patient survival and immunotherapy efficacy in PDAC. This model serves as a valuable prognostic biomarker and provides insights into the immune mechanisms of PDAC, supporting the strategy of inducing TLS formation to augment cancer immunotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • SYK (Spleen tyrosine kinase) • CXCL11 (C-X-C Motif Chemokine Ligand 11) • LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase) • VAV1 (Vav Guanine Nucleotide Exchange Factor 1) • CASC8 (Cancer Susceptibility 8) • CHGA (Chromogranin A) • DUSP26 (Dual Specificity Phosphatase 26)
    1m
    NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2027 --> Aug 2026 | Trial primary completion date: Jun 2027 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • SSTR2 (Somatostatin Receptor 2) • SYP (Synaptophysin) • CHGA (Chromogranin A)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Lutathera (lutetium Lu 177 dotatate) • AAA603
    1m
    Endometriosis Is Associated with Increased Serum and Peritoneal Fluid Concentrations of Chromogranin A and Its Derivatives. (PubMed, J Clin Med)
    Receiver operating characteristic (ROC) analysis further confirmed that endometriosis is associated with increased circulating CgA, catestatin, and pancreastatin levels, suggesting that they may be considered markers of endometriosis. The upregulation of CgA and its derivatives in endometriosis may indicate their role in the disease pathogenesis and implicate them as potential diagnostic markers and/or therapeutic targets.
    Journal
    |
    CHGA (Chromogranin A)
    1m
    RPS6KA1 Remodels Fatty Acid Metabolism and Suppresses Malignant Progression in Colorectal Cancer. (PubMed, Biomedicines)
    In vitro and in vivo experiments demonstrated that RPS6KA1 inhibits malignant progression of colon cancer and modulates fatty acid metabolism. Integrated multi-dimensional bioinformatic and experimental analyses reveal that RPS6KA1 remodels fatty acid metabolism and suppresses malignant progression, indicating its value as a prognostic biomarker in CRC and providing new insights for therapeutic strategies.
    Journal
    |
    CD8 (cluster of differentiation 8) • CHGA (Chromogranin A)
    1m
    A Case of Appendiceal Neuroendocrine Tumor Diagnosed after Appendectomy (PubMed, Gan To Kagaku Ryoho)
    Appendix NETs are often diagnosed incidentally, as in this case. In treating appendicitis, it is essential to perform pathological examination of the resected specimen.
    Journal
    |
    SYP (Synaptophysin) • CHGA (Chromogranin A)
    2ms
    Molecular and histopathological insights into renal neuroendocrine tumors (RenNETs): A comprehensive study. (PubMed, Pathol Res Pract)
    These findings underscore the necessity for molecular profiling in guiding the diagnosis and potential therapeutic strategies for RenNETs. Further studies are warranted to explore the mechanisms underlying their pathogenesis and clinical behavior.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MCL1 (Myeloid cell leukemia 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway) • ABCC2 (ATP Binding Cassette Subfamily C Member 2) • ERCC6 (Excision repair cross-complementation group 6) • SYP (Synaptophysin) • CHGA (Chromogranin A)
    |
    TP53 mutation
    2ms
    Expression and Diagnostic Significance of Clinical Routine VMAT2 Immunostaining in Neuroendocrine Neoplasia: A Study of Institutional Cases. (PubMed, J Histochem Cytochem)
    Sensitivity was highest in small-intestinal and gastric NETs and more variable in pancreatic NETs. These results support VMAT2 as a robust, differentiation-linked neuroendocrine marker whose inclusion in modern immunohistochemical panels may improve diagnostic accuracy.
    Journal
    |
    SYP (Synaptophysin) • CHGA (Chromogranin A)